These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 27956401)
21. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk]. MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517 [No Abstract] [Full Text] [Related]
22. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Bonadonna RC; Borghi C; Consoli A; Volpe M Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139 [TBL] [Abstract][Full Text] [Related]
23. Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258 [No Abstract] [Full Text] [Related]
24. EMPA-REG OUTCOME: The Cardiologist's Point of View. Pham SV; Chilton R Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181 [TBL] [Abstract][Full Text] [Related]
25. Implications of the EMPA-REG Trial for Clinical Care and Research. Stamatouli AM; Inzucchi SE Curr Diab Rep; 2016 Dec; 16(12):131. PubMed ID: 27812962 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Staels B Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184 [TBL] [Abstract][Full Text] [Related]
32. Increased grip strength with sodium-glucose cotransporter 2. Sano M; Meguro S; Kawai T; Suzuki Y J Diabetes; 2016 Sep; 8(5):736-7. PubMed ID: 27038414 [No Abstract] [Full Text] [Related]
33. [Empagliflozin: another of silent revolutioners]. Kvapil M Vnitr Lek; 2014 Nov; 60(11):924-5. PubMed ID: 25612346 [No Abstract] [Full Text] [Related]
34. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus. Peters MN; Pollock JS; Rajagopalan S J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087 [No Abstract] [Full Text] [Related]
35. EMPA-REG OUTCOME: The Nephrologist's Point of View. Wanner C Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179 [TBL] [Abstract][Full Text] [Related]
36. SGLT2 inhibitors for primary prevention of cardiovascular events. Raz I; Cernea S; Cahn A J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238 [No Abstract] [Full Text] [Related]
37. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634 [TBL] [Abstract][Full Text] [Related]
38. Dapagliflozine (Farxiga) for type 2 diabetes. Med Lett Drugs Ther; 2014 Feb; 56(1436):13-5. PubMed ID: 24663030 [No Abstract] [Full Text] [Related]
39. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783 [TBL] [Abstract][Full Text] [Related]
40. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Perreault L Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]